Know Cancer

forgot password

Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early

Phase 1/Phase 2
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early

Breast cancer is the most common malignancy affecting females in northern Europe and North
America, corresponding to an age-corrected annual incidence of 100 to 120 per 100000
females. Approximately 30-40% of all patients treated with curative intent will develop
metastatic disease. Perioperative systemic treatment has made a major impact on relapse-free
and overall survival of women with early-stage breast cancer [ , ] with therapeutic
strategies being based on the endocrine responsiveness and the estimated risk of relapse
defined by tumor size, axillary lymph node involvement, histologic and nuclear grade,
lymphatic and/or vascular invasion, HER2/neu-overexpression and age [ ]. Perioperative
therapy has traditionally been administered postoperatively, but chemotherapy is
increasingly utilized in the preoperative setting as it can significantly improve the rate
of breast conserving surgery, and new regimens can be evaluated rapidly and more precisely.

Inclusion Criteria:

- Histologically confirmed breast cancer

- T1c N1-2 or T2 N0-2 disease

- HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or
amplification of the HER2 gene on fluorescence in situ hybridization (FISH)

- No prior systemic treatment regimens for breast cancer

- Adequate hematologic function (ANC 1500 cells/µl, platelet count 100000/µl, and
hemoglobin 8g/dl).

- Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or
creatinine clearance >60 ml/min

- Bilirubin level < 1.5 X ULN

- Normal cardiac function with a left ventricular ejection fraction of at least 50% (as
assessed by quantitative echocardiogram or MUGA scan)

- Karnofsky performance status 80%

- Age 18 years

- If the patient is of childbearing potential, she agrees to: comply with effective
contraceptive measures, has been using adequate contraception since the last menses,
will use adequate contraception during the study, and has a negative pregnancy test
within one week of study entry

- Written informed consent prior to admission to this study

Exclusion Criteria:

- Male patients

- Inflammatory or bilateral breast cancer

- Evidence of distant metastases

- Previous systemic or local treatment for breast cancer (including surgery,
radiotherapy, cytotoxic and endocrine treatments)

- Past or current history of other neoplasms, except for

- Curatively treated non-melanoma skin cancer

- Adequately treated in situ carcinoma of the cervix

- Other cancer curatively treated and with no evidence of disease for at least 5 years

- Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia
requiring medication, severe conduction abnormalities, clinically significant
valvular disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled
hypertension (resting diastolic blood pressure >115 mmHg), prior myocardial
infarction, CHF, or other cardiomyopathy

- Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC

- Serious intercurrent medical or psychiatric illness, including serious active

- Concurrent treatment with other experimental drugs. Participation in another clinical
trial with any investigational drug within 30 days prior to study entry.

- Detained persons or prisoners

- Pregnant or nursing women

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine the optimal doses for NPLD, paclitaxel and lapatinib (phase I)

Outcome Time Frame:

every 3 weeks

Safety Issue:


Principal Investigator

Dirk Elling

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sana Klinikum Lichtenberg, Berlin


Germany: Federal Institute for Drugs and Medical Devices

Study ID:




Start Date:

September 2007

Completion Date:

September 2016

Related Keywords:

  • Breast Cancer
  • HER2-positive
  • early breast cancer
  • Breast Neoplasms